Simpler Grants.gov #HT942526LCRPTRA

Army and DHA Seek Proposals for Advanced Lung Cancer Translational Research and Pilot Clinical Trials

The Department of the Army, in partnership with the Defense Health Agency (DHA) and Congressionally Directed Medical Research Programs (CDMRP), is soliciting proposals for the FY26 Lung Cancer Research Program Translational Research Award (TRA): - Government Buyer: - Department of the Army, US Army Medical Research Acquisition Activity (USAMRAA) - Defense Health Agency (DHA) Research and Development, CDMRP - No specific OEMs or commercial vendors are named, as this is a research grant opportunity rather than a product or equipment procurement - Products/Services Requested: - Advanced translational research in lung cancer, addressing at least one FY26 LCRP area of emphasis - Two funding levels: - Level 1: Advanced/late-stage preclinical work or correlative studies (up to $1.35M, max 3 years) - Level 2: Pilot clinical trials of novel interventions (up to $1.85M, max 4 years) - Approximately $9.1 million in total funding, with about six awards expected - Unique/Notable Requirements: - Research must demonstrate military health relevance - No cost sharing or matching required - Eligibility is unrestricted - Applicants must have active registrations in SAM.gov, eBRAP.org, and Grants.gov - Place of Performance and Key Facilities: - US Army Medical Research Acquisition Activity (USAMRAA) - Defense Health Agency Research and Development - U.S. Department of Veterans Affairs - U.S. Department of War (historical reference) - No product part numbers, OEMs, or commercial product line items are specified, as this is a grant for research services

Description

The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research aimed at transforming promising ideas in lung cancer into clinical applications. The research must address at least one of the FY26 LCRP areas of emphasis. This funding mechanism supports a broad range of translational studies and allows application submission under two funding levels: Level 1 for advanced/late-stage preclinical work or correlative studies, and Level 2 for pilot clinical trials of novel interventions. The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $9.1 million to fund about six TRA applications, with total cost caps of $1.35 million per award for Funding Level 1 and $1.85 million per award for Funding Level 2. The maximum period of performance is 3 years for Level 1 awards and 4 years for Level 2 awards.

View original listing